Paratek Pharmaceuticals received FDA approval on October 2, 2018, to market the intravenous antibiotic NUZYRA (omadacycline) under New Drug Application NDA209817. The launch of this broad-spectrum agent is expected to strengthen the company’s position in a rapidly growing multi-sector market, particularly by capturing physician share ahead of coming expirations to key competitors.